CASI Pharmaceuticals Stock News

CASI Pharmaceuticals, Inc. (CASI) with the stream of -5.75% also noticed, India Superior Drilling Products, Inc. (SDPI) encountered a rapid change of -10.81% in the last hour of trading session. The post Stock on fire: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Superior Drilling Products, Inc. (AMEX:SDPI) appeared first on Stocks Equity .

Almaden Minerals Ltd. (AAU) with the stream of 0.29% also noticed, India CASI Pharmaceuticals, Inc. (CASI) encountered a rapid change of -5.75% in the last hour of Fridays trading session. The post Most Prominent Stock: Almaden Minerals Ltd. (AMEX:AAU), CASI Pharmaceuticals, Inc. (NASDAQ:CASI) appeared first on Stocks Equity .

Marshall Wace LLP bought a new stake in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) in the 2nd quarter, according to its most recent filing with the SEC. The fund bought 223,709 shares of the biotechnology companys stock, valued at approximately $347,000. Marshall Wace LLP owned 0.16% of CASI Pharmaceuticals at the end of the most recent reporting []

CASI Pharmaceuticals, Inc. (CASI) with the stream of -5.22% also noticed, India Zomedica Corp. (ZOM) encountered a rapid change of -2.04% in the last hour of trading session. CASI Pharmaceuticals, The post Bright Stock Buzz: CASI Pharmaceuticals, Inc. (NASDAQ:CASI), Zomedica Corp. (AMEX:ZOM) appeared first on Stocks Equity .

The trading price of CASI Pharmaceuticals Inc. (NASDAQ:CASI) floating lower at last check on Tuesday, November 23, closing at $0.90, -3.88% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

In todays recent session, 2.18 million shares of the CASI Pharmaceuticals Inc. (NASDAQ:CASI) have been traded, and its beta is 0.32. Most recently the companys share price was $0.98, and it changed around $0.05 or 5.25% from the last close, which brings the market valuation of the company to $132.24M. CASI at last check was CASI Pharmaceuticals Inc. (NASDAQ: CASI) Stock Forecast 2021: $6.00 Per Share With Bullish Signs Read More »

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) CEO Wei-Wu He purchased 200,000 shares of the companys stock in a transaction that occurred on Wednesday, November 17th. The shares were purchased at an average price of $0.99 per share, for a total transaction of $198,000.00. The purchase was disclosed in a filing with the SEC, which is available at []

Related Stocks: CASI ,

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Research analysts at Oppenheimer decreased their FY2021 earnings per share (EPS) estimates for shares of CASI Pharmaceuticals in a note issued to investors on Monday, November 15th. Oppenheimer analyst L. Gershell now anticipates that the biotechnology company will post earnings of ($0.28) per share for the year, down from their []

CASI Pharmaceuticals (NASDAQ:CASI) and Ambrx Biopharma (NYSE:AMAM) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, risk, earnings, analyst recommendations, dividends and valuation. Analyst Recommendations This is a summary of current ratings and recommmendations for CASI Pharmaceuticals and []

Schonfeld Strategic Advisors LLC purchased a new stake in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 20,600 shares of the biotechnology companys stock, valued at approximately $32,000. A number of other institutional investors and hedge funds also []

CASI Pharmaceuticals Inc. (NASDAQ:CASI) price closed higher on Wednesday, November 17, jumping 2.08% above its previous close. >> 7 Top Picks for the Post-Pandemic Economy > 7 Top Picks for the Post-Pandemic Economy

Equities research analysts expect that CASI Pharmaceuticals, Inc. (NASDAQ:CASI) will announce earnings per share of ($0.06) for the current fiscal quarter, Zacks reports. Two analysts have made estimates for CASI Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.06). CASI Pharmaceuticals reported earnings per share […]

CASI Pharmaceuticals (NASDAQ:CASI) posted its earnings results on Thursday. The biotechnology company reported ($0.07) earnings per share for the quarter, missing the Thomson Reuters consensus estimate of ($0.06) by ($0.01), MarketWatch Earnings reports. CASI Pharmaceuticals had a negative net margin of 236.69% and a negative return on equity of 56.52%. During the same period in []

CASI Pharmaceuticals, Inc. (CASI) CEO Wei-Wu He on Q3 2021 Results - Earnings Call Transcript